Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Acedo, Alberto ^a   Sanz, David J ^a   Durán, Mercedes ^a   Infante, Mar ^a   Pérez Cabornero, Lucía ^a   Miner, Cristina ^a   Velasco, Eladio A ^a  

^a Universidad de Valladolid y Consejo Superior de Investigaciones Científicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; DNA; NUCLEOTIDE; RNA; BRCA2 PROTEIN, HUMAN; RNA ISOFORM;

ARTICLE; BIOINFORMATICS; BREAST CANCER; COMPREHENSIVE SPLICING FUNCTIONAL ANALYSIS; CONTROLLED STUDY; EXON; FEMALE; FLUORESCENCE; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HYBRID GENE; HYBRID MINIGENE; INTRON; LYMPHOCYTE; OVARY CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; BREAST TUMOR; GENETIC RECOMBINATION; GENETICS; HELA CELL; RNA SPLICING; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; BREAST NEOPLASMS; DNA; FEMALE; GENES, BRCA2; GENETIC VARIATION; HELA CELLS; HUMANS; RECOMBINATION, GENETIC; RNA ISOFORMS; RNA SPLICE SITES; RNA SPLICING; SEQUENCE DELETION;

EID: 84861391312     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3202     Document Type: Article

References (52)

1. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M, . the Breast Cancer Linkage Consortium Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62:676-689. 10.1086/301749, 1376944, 9497246, the Breast Cancer Linkage Consortium.
2. Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet 2008, 40:17-22. 10.1038/ng.2007.53, 18163131.
3. The Breast Cancer Information Core Database. (Accessed June 2011)., http://research.nhgri.nih.gov/projects/bic
4. Vallon-Christersson J, Cayanan C, Haraldsson K, Loman N, Bergthorsson JT, Brondum-Nielsen K, Gerdes AM, Moller P, Kristoffersson U, Olsson H, Borg A, Monteiro AN. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum Mol Genet 2001, 10:353-360. 10.1093/hmg/10.4.353, 11157798.
5. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, Wadum L, Johnson K, Mentlick J, Tavtigian SV, Goldgar DE, Couch FJ. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008, 68:3523-3531. 10.1158/0008-5472.CAN-07-1587, 2936780, 18451181.
6. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol 2011, 22(Suppl 1):i18-i23.
7. Kuznetsov SG, Liu P, Sharan SK. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med 2008, 14:875-881. 10.1038/nm.1719, 2640324, 18607349.
8. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 2004, 75:535-544. 10.1086/424388, 1182042, 15290653.
9. Gomez Garcia EB, Oosterwijk JC, Timmermans M, van Asperen CJ, Hogervorst FB, Hoogerbrugge N, Oldenburg R, Verhoef S, Dommering CJ, Ausems MG, van Os TA, van der Hout AH, Ligtenberg M, van den OA, van der Luijt RB, Wijnen JT, Gille JJ, Lindsey PJ, Devilee P, Blok MJ, Vreeswijk MP. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 2009, 11:R8. 10.1186/bcr2223, 2687711, 19200354.
10. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. Nat Rev Genet 2007, 8:749-761. 10.1038/nrg2164, 17726481.
11. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002, 3:285-298. 10.1038/nrg775, 11967553.
12. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease?. FEBS Lett 2005, 579:1900-1903. 10.1016/j.febslet.2005.02.047, 15792793.
13. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet 1992, 90:41-54.
14. Sanz DJ, Acedo A, Infante M, Duran M, Perez-Cabornero L, Esteban-Cardenosa E, Lastra E, Pagani F, Miner C, Velasco EA. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. Clin Cancer Res 2010, 16:1957-1967. 10.1158/1078-0432.CCR-09-2564, 20215541.
15. Pagani F, Stuani C, Tzetis M, Kanavakis E, Efthymiadou A, Doudounakis S, Casals T, Baralle FE. New type of disease causing mutations: the example of the composite exonic regulatory elements of splicing in CFTR exon 12. Hum Mol Genet 2003, 12:1111-1120. 10.1093/hmg/ddg131, 12719375.
16. Brandao RD, van Roozendaal K, Tserpelis D, Garcia EG, Blok MJ. Characterisation of unclassified variants in the BRCA1/2 genes with a putative effect on splicing. Breast Cancer Res Treat 2011, 129:971-982. 10.1007/s10549-011-1599-7, 21638052.
17. Menendez M, Castellsague J, Mirete M, Pros E, Feliubadalo L, Osorio A, Calaf M, Tornero E, Del Valle J, Fernandez-Rodriguez J, Quiles F, Salinas M, Velasco A, Teule A, Brunet J, Blanco I, Capella G, Lazaro C. Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes. Breast Cancer Res Treat 2012, 132:979-992. 10.1007/s10549-011-1661-5, 21735045.
18. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, Berthet P, Chevrier A, Dugast C, Layet V, Rossi A, Lidereau R, Frebourg T, Hardouin A, Tosi M. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008, 45:438-446. 10.1136/jmg.2007.056895, 18424508.
19. Thery JC, Krieger S, Gaildrat P, Revillion F, Buisine MP, Killian A, Duponchel C, Rousselin A, Vaur D, Peyrat JP, Berthet P, Frebourg T, Martins A, Hardouin A, Tosi M. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet 2011, 19:1052-1058. 10.1038/ejhg.2011.100, 21673748.
20. Thomassen M, Blanco A, Montagna M, Hansen TV, Pedersen IS, Gutierrez-Enriquez S, Menendez M, Fachal L, Santamarina M, Steffensen AY, Jonson L, Agata S, Whiley P, Tognazzo S, Tornero E, Jensen UB, Balmana J, Kruse TA, Goldgar DE, Lazaro C, Diez O, Spurdle AB, Vega A. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Res Treat 2012, 132:1009-1023. 10.1007/s10549-011-1674-0, 21769658.
21. Baralle D, Lucassen A, Buratti E. Missed threads. The impact of pre-mRNA splicing defects on clinical practice. EMBO Rep 2009, 10:810-816. 10.1038/embor.2009.170, 2726684, 19648957.
22. Cooper TA. Use of minigene systems to dissect alternative splicing elements. Methods 2005, 37:331-340. 10.1016/j.ymeth.2005.07.015, 16314262.
23. Infante M, Duran M, Esteban-Cardenosa E, Miner C, Velasco E. High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-Leon (central Spain). J Hum Genet 2006, 51:611-617. 10.1007/s10038-006-0404-7, 16758124.
24. Esteban-Cardenosa E, Duran M, Infante M, Velasco E, Miner C. High-throughput mutation detection method to scan BRCA1 and BRCA2 based on heteroduplex analysis by capillary array electrophoresis. Clin Chem 2004, 50:313-320. 10.1373/clinchem.2003.023614, 14684619.
25. Velasco E, Infante M, Duran M, Perez-Cabornero L, Sanz DJ, Esteban-Cardenosa E, Miner C. Heteroduplex analysis by capillary array electrophoresis for rapid mutation detection in large multiexon genes. Nat Protoc 2007, 2:237-246.
26. Human Genome Variation Society Guidelines for mutation nomenclature. (Accessed September 2011), Human Genome Variation Society., http://www.hgvs.org/rec.html
27. Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in Genie. J Comput Biol 1997, 4:311-323. 10.1089/cmb.1997.4.311, 9278062.
28. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud C. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 2009, 37:e67. 10.1093/nar/gkp215, 2685110, 19339519.
29. Pettigrew C, Wayte N, Lovelock PK, Tavtigian SV, Chenevix-Trench G, Spurdle AB, Brown MA. Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Res 2005, 7:R929-R939. 10.1186/bcr1324, 1410749, 16280041.
30. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, Valentin F, Wallace IM, Wilm A, Lopez R, Thompson JD, Gibson TJ, Higgins DG. Clustal W and Clustal X version 2.0. Bioinformatics 2007, 23:2947-2948. 10.1093/bioinformatics/btm404, 17846036.
31. Soule HD, Maloney TM, Wolman SR, Peterson WD, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990, 50:6075-6086.
32. METHODBOOK PCR mutagenesis. (Accessed January 2010), METHODBOOK., http://www.methodbook.net/pcr/pcrmut.html
33. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002, 297:606-9. 10.1126/science.1073834, 12065746.
34. Buratti E, Baralle M, Baralle FE. Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Res 2006, 34:3494-3510. 10.1093/nar/gkl498, 1524908, 16855287.
35. Ast G. How did alternative splicing evolve?. Nat Rev Genet 2004, 5:773-782.
36. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008, 24:7-10. 10.1016/j.tig.2007.10.001, 18054115.
37. Michael IP, Kurlender L, Memari N, Yousef GM, Du D, Grass L, Stephan C, Jung K, Diamandis EP. Intron retention: a common splicing event within the human kallikrein gene family. Clin Chem 2005, 51:506-515. 10.1373/clinchem.2004.042341, 15650036.
38. The International Agency for Research on Cancer (IARC) Alignment of the BRCA2 protein (12 species). (Accessed September 2011), The International Agency for Research on Cancer (IARC)., http://agvgd.iarc.fr/BRCA2_Align.htm
39. Infante M, Duran M, Acedo A, Perez-Cabornero L, Sanz DJ, Garcia-Gonzalez M, Beristain E, Esteban-Cardenosa E, de la Hoya M, Teule A, Vega A, Tejada MI, Lastra E, Miner C, Velasco EA. BRCA1 5272-1G > A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin. Clin Genet 2010, 77:60-69. 10.1111/j.1399-0004.2009.01272.x, 19912264.
40. Zhang C, Li WH, Krainer AR, Zhang MQ. RNA landscape of evolution for optimal exon and intron discrimination. Proc Natl Acad Sci USA 2008, 105:5797-5802. 10.1073/pnas.0801692105, 2311341, 18391195.
41. Whiley PJ, Guidugli L, Walker LC, Healey S, Thompson BA, Lakhani SR, Da Silva LM, Tavtigian SV, Goldgar DE, Brown MA, Couch FJ, Spurdle AB. Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary. Hum Mutat 2011, 32:678-687. 10.1002/humu.21495, 21394826.
42. Hinzpeter A, Aissat A, Sondo E, Costa C, Arous N, Gameiro C, Martin N, Tarze A, Weiss L, de Becdelievre A, Costes B, Goossens M, Galietta LJ, Girodon E, Fanen P. Alternative splicing at a NAGNAG acceptor site as a novel phenotype modifier. PLoS Genet 2010, 6:e100153.
43. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonnet D, Lenoir GM, Mazoyer S. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum Mol Genet 2002, 11:2805-2814. 10.1093/hmg/11.23.2805, 12393792.
44. Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, Vagner S, Toulas C. The c.5242C > A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 2010, 120:391-399. 10.1007/s10549-009-0392-3, 19404736.
45. Whiley PJ, Pettigrew CA, Brewster BL, Walker LC, Spurdle AB, Brown MA. Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts. BMC Med Genet 2010, 11:80. 2897790, 20507642.
46. Hertel KJ. Combinatorial control of exon recognition. J Biol Chem 2008, 283:1211-1215.
47. Goina E, Skoko N, Pagani F. Binding of DAZAP1 and hnRNPA1/A2 to an exonic splicing silencer in a natural BRCA1 exon 18 mutant. Mol Cell Biol 2008, 28:3850-3860. 10.1128/MCB.02253-07, 2423284, 18391021.
48. Steiner B, Truninger K, Sanz J, Schaller A, Gallati S. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles. Hum Mutat 2004, 24:120-129. 10.1002/humu.20064, 15241793.
49. Gaildrat P, Krieger S, Thery JC, Killian A, Rousselin A, Berthet P, Frebourg T, Hardouin A, Martins A, Tosi M. The BRCA1 c.5434C- > G (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements. J Med Genet 2010, 47:398-403. 10.1136/jmg.2009.074047, 20522429.
50. Milne RL, Osorio A, Cajal TR, Vega A, Llort G, de la Hoya M, Diez O, Alonso MC, Lazaro C, Blanco I, Sanchez-de-Abajo A, Caldes T, Blanco A, Grana B, Duran M, Velasco E, Chirivella I, Cardenosa EE, Tejada MI, Beristain E, Miramar MD, Calvo MT, Martinez E, Guillen C, Salazar R, San RC, Antoniou AC, Urioste M, Benitez J. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. Clin Cancer Res 2008, 14:2861-2869. 10.1158/1078-0432.CCR-07-4436, 18451254.
51. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, Tavtigian SV, Monteiro AN, Iversen ES, Couch FJ, Goldgar DE. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007, 81:873-883. 10.1086/521032, 2265654, 17924331.
52. Dosil V, Tosar A, Canadas C, Perez-Segura P, Diaz-Rubio E, Caldes T, de la Hoya M. Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C > T as a case study. Clin Chem 2010, 56:53-61. 10.1373/clinchem.2009.132274, 19892845.